

CIRM Funded Clinical Trials

**Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis**

<b>Disease Area:</b>	Osteoarthritis
<b>Investigator:</b>	Kristen Johnson
<b>Institution:</b>	Calibr
<b>CIRM Grant:</b>	CLIN2-10388
<b>Award Value:</b>	\$8,447,523
<b>Trial Sponsor:</b>	Calibr
<b>Trial Stage:</b>	Phase 1
<b>Trial Status:</b>	Completed
<b>Targeted Enrollment:</b>	60
<b>ClinicalTrials.gov ID:</b>	NCT03133676



Kristen Johnson

**Details:**

Researchers at the California Institute for Biomedical Research (CALIBR) have been awarded \$8.447 million to test KA34, a drug that, in preclinical tests, recruits stem cells to create new cartilage in areas damaged by osteoarthritis. CIRM funded the research that developed this technology and now this Phase 1 trial will test this stem cell directed treatment in people with osteoarthritis of the knee, hopefully slowing down or even halting the progression of the disease.

**Design:**

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study.

**Goal:**

This study will evaluate the safety and tolerability of KA34 when administered to patients with osteoarthritis of the knee.

**Updates:**

Podcast - Dr. Kristen Johnson & Dr. Maria Millan: Regenerative Medicine for Osteoarthritis

Contact Trial Sponsor